A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topiramate for the Treatment of Compulsive Buying Disorder

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMATTOS, Cristiana de
dc.contributor.authorKIM, Hyoun S.
dc.contributor.authorMARASALDI, Renata F.
dc.contributor.authorREQUIAO, Marinalva G.
dc.contributor.authorOLIVEIRA, Elen Cristina de
dc.contributor.authorFILOMENSKY, Tatiana
dc.contributor.authorTAVARES, Hermano
dc.date.accessioned2020-06-01T14:57:30Z
dc.date.available2020-06-01T14:57:30Z
dc.date.issued2020
dc.description.abstractBackground Topiramate is an anticonvulsant that has shown promise as a pharmacological agent for the treatment of addictive disorders, including compulsive buying disorder (CBD). The aim of the present study was to examine the efficacy of topiramate in the treatment of CBD and its associated characteristics using a 12-week randomized, double-blind, placebo-controlled design. Methods Fifty patients seeking treatment of CBD who met the inclusion criteria were randomly assigned to either the experimental group (n = 25) or the control group (n = 25). Both groups received 4 sessions of psychoeducation. Results Forty-four participants completed the follow-up with no differences in the rate of dropout between groups. There were no differences between participants who received topiramate or placebo in reducing CBD symptoms assessed by the primary outcome scale (Yale-Brown Obsessive-Compulsive Scale - Shopping Version). However, participants who received topiramate were significantly more likely to show clinical improvement when assessed by a secondary outcome measure, the Compulsive Buying Follow-Up Scale. In addition, there was a trend among participants who received topiramate to report improvements in aspects of hoarding and impulsivity compared with the control group. There were significant improvements in comorbid depression and social adjustments over time, but no group x time interaction was found. Conclusions The results do not provide support for the use of topiramate in the treatment of CBD. Future investigation with larger and representative samples and longer follow-up period are needed.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipBrazilian National Council for Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq) [445465/2014-0]
dc.identifier.citationJOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, v.40, n.2, p.186-190, 2020
dc.identifier.doi10.1097/JCP.0000000000001183
dc.identifier.eissn1533-712X
dc.identifier.issn0271-0749
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/36054
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofJournal of Clinical Psychopharmacology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subjectcompulsive buying disordereng
dc.subjectclinical trialeng
dc.subjectdouble blindeng
dc.subjectplacebo controlledeng
dc.subjecttopiramateeng
dc.subject.othercognitive-behavioral therapyeng
dc.subject.otherportuguese versioneng
dc.subject.otherscaleeng
dc.subject.otherreliabilityeng
dc.subject.othervalidationeng
dc.subject.otherinventoryeng
dc.subject.othervalidityeng
dc.subject.wosPharmacology & Pharmacyeng
dc.subject.wosPsychiatryeng
dc.titleA 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topiramate for the Treatment of Compulsive Buying Disordereng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalKIM, Hyoun S.:Univ Calgary, Addict Behav Lab, Dept Psychol, Calgary, AB, Canada
hcfmusp.citation.scopus6
hcfmusp.contributor.author-fmusphcCRISTIANA NICOLI DE MATTOS
hcfmusp.contributor.author-fmusphcRENATA FERNANDES MARANSALDI DE LIMA
hcfmusp.contributor.author-fmusphcMARINALVA GONCALVES REQUIAO
hcfmusp.contributor.author-fmusphcELEN CRISTINA BATISTA DE OLIVEIRA
hcfmusp.contributor.author-fmusphcTATIANA ZAMBRANO FILOMENSKY
hcfmusp.contributor.author-fmusphcHERMANO TAVARES
hcfmusp.description.beginpage186
hcfmusp.description.endpage190
hcfmusp.description.issue2
hcfmusp.description.volume40
hcfmusp.origemWOS
hcfmusp.origem.pubmed32134854
hcfmusp.origem.scopus2-s2.0-85081530604
hcfmusp.origem.wosWOS:000526401500012
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAmorim Patricia, 2000, Revista Brasileira de Psiquiatria, V22, P106eng
hcfmusp.relation.referenceBECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5eng
hcfmusp.relation.referenceBerlin HA, 2013, WORLD J BIOL PSYCHIA, V14, P121, DOI 10.3109/15622975.2011.560964eng
hcfmusp.relation.referenceBlack DW, 2001, CNS DRUGS, V15, P17, DOI 10.2165/00023210-200115010-00003eng
hcfmusp.relation.referenceBullock K, 2003, DRUG TODAY, V39, P695, DOI 10.1358/dot.2003.39.9.799477eng
hcfmusp.relation.referencede Brito AMC, 2017, J GAMBL STUD, V33, P249, DOI 10.1007/s10899-016-9620-zeng
hcfmusp.relation.referenceChow S, 2008, SAMPLE SIZE CALCULAT, P89eng
hcfmusp.relation.referenceClaudino AM, 2007, J CLIN PSYCHIAT, V68, P1324, DOI 10.4088/JCP.v68n0901eng
hcfmusp.relation.referenceDavid V, 1998, EUR J NEUROSCI, V10, P1394, DOI 10.1046/j.1460-9568.1998.00150.xeng
hcfmusp.relation.referencede Mattos CN, 2019, PSYCHIAT RES, V282, DOI 10.1016/j.psychres.2018.12.078eng
hcfmusp.relation.referenceFilomensky TZ, 2012, COMPR PSYCHIAT, V53, P554, DOI 10.1016/j.comppsych.2011.09.005eng
hcfmusp.relation.referenceFirst M, 1997, STRUCTURED CLIN INTEeng
hcfmusp.relation.referenceFontenelle IS, 2010, PSYCHOL REP, V106, P279, DOI 10.2466/PR0.106.1.279-296eng
hcfmusp.relation.referenceGorenstein C, 2002, J AFFECT DISORDERS, V69, P167, DOI 10.1016/S0165-0327(01)00300-7eng
hcfmusp.relation.referenceGrant JE, 2016, JAMA PSYCHIAT, V73, P490, DOI 10.1001/jamapsychiatry.2016.0060eng
hcfmusp.relation.referenceGuy W, 1976, ECDEU ASSESSMENT MAN, P76eng
hcfmusp.relation.referenceHague B, 2016, J BEHAV ADDICT, V5, P379, DOI 10.1556/2006.5.2016.064eng
hcfmusp.relation.referenceJohnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3eng
hcfmusp.relation.referenceJohnson BA, 2013, ADDICT BIOL, V18, P405, DOI 10.1111/j.1369-1600.2012.00499.xeng
hcfmusp.relation.referenceLeite PL, 2014, COMPR PSYCHIAT, V55, P1462, DOI 10.1016/j.comppsych.2014.04.012eng
hcfmusp.relation.referenceLeite Priscilla Lourenço, 2011, J. bras. psiquiatr., V60, P176, DOI 10.1590/S0047-20852011000300005eng
hcfmusp.relation.referenceLingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1eng
hcfmusp.relation.referenceMalloy-Diniz LF, 2015, REV BRAS PSIQUIATR, V37, P245, DOI 10.1590/1516-4446-2014-1599eng
hcfmusp.relation.referenceMitchell JE, 2006, BEHAV RES THER, V44, P1859, DOI 10.1016/j.brat.2005.12.009eng
hcfmusp.relation.referenceMueller A, 2007, BEHAV RES THER, V45, P2754, DOI 10.1016/j.brat.2007.07.012eng
hcfmusp.relation.referencePorter Roger J, 2012, Handb Clin Neurol, V108, P663, DOI 10.1016/B978-0-444-52899-5.00021-6eng
hcfmusp.relation.referenceSheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whieng
hcfmusp.relation.referenceSoares C, 2016, CNS DRUGS, V30, P281, DOI 10.1007/s40263-016-0324-9eng
hcfmusp.relation.referenceToledo EL, 2015, J CLIN PSYCHIAT, V76, P447, DOI 10.4088/JCP.13m08964eng
hcfmusp.relation.referenceWorld Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication59dcc252-7745-4519-8745-e62490bad44a
relation.isAuthorOfPublicatione66994ed-1211-4734-9d90-2f824d7ace5c
relation.isAuthorOfPublicationbdaddbc0-1cd9-4d72-8ddf-abdf10c3a5ac
relation.isAuthorOfPublicationa471bc41-2c9c-4c78-8af5-ca23fa89e66e
relation.isAuthorOfPublication9c38df3b-adfd-4900-92ea-5efeee38aaea
relation.isAuthorOfPublication7969a81a-9a0a-4d8c-8ff5-03bb26878777
relation.isAuthorOfPublication.latestForDiscovery59dcc252-7745-4519-8745-e62490bad44a
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23